{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:54:31Z","timestamp":1787842471056,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["546272"],"award-info":[{"award-number":["546272"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1045862"],"award-info":[{"award-number":["1045862"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartandlung.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.hrtlng.2021.09.005","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T19:00:33Z","timestamp":1635534033000},"page":"40-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Antihypertensive drug class in combination with lipid lowering treatment for primary prevention of cardiovascular disease in the elderly"],"prefix":"10.1016","volume":"51","author":[{"given":"Zhen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enayet K.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Breslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.hrtlng.2021.09.005_bib0001","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","article-title":"Blood-pressure and cholesterol lowering in persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hrtlng.2021.09.005_bib0002","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5455\/msm.2017.29.35-39","article-title":"Population attributable fraction for cardiovascular diseases risk factors in selected countries: a comparative study","volume":"29","author":"Pirani","year":"2017","journal-title":"Mater Sociomed"},{"issue":"3","key":"10.1016\/j.hrtlng.2021.09.005_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002539","article-title":"Primary prevention of cardiovascular disease: the past, present, and future of blood pressure- and cholesterol-lowering treatments","volume":"15","author":"Leening","year":"2018","journal-title":"PLoS Med"},{"issue":"24","key":"10.1016\/j.hrtlng.2021.09.005_bib0004","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1161\/01.CIR.0000143085.86697.13","article-title":"Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients","volume":"110","author":"Koh","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hrtlng.2021.09.005_bib0005","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.0000166722.91714.ba","article-title":"Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes","volume":"45","author":"Koh","year":"2005","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.hrtlng.2021.09.005_bib0006","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting\u2013enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hrtlng.2021.09.005_bib0007","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1440-1681.1997.tb01806.x","volume":"24","author":"Reid","year":"1997","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"10.1016\/j.hrtlng.2021.09.005_bib0008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"issue":"12","key":"10.1016\/j.hrtlng.2021.09.005_bib0009","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"12","author":"Vandenbroucke","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.hrtlng.2021.09.005_bib0010","unstructured":"Alliance N.V.D.P. Guidelines for the management of absolute cardiovascular disease risk. National Vascular Disease Prevention Alliance (NVDPA). https:\/\/www.heartfoundation.org.au\/images\/uploads\/publications\/Absolute-CVD-Risk-Full-Guidelines.pdf"},{"issue":"27","key":"10.1016\/j.hrtlng.2021.09.005_bib0011","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting fine-gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.hrtlng.2021.09.005_bib0012","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1253\/circj.CJ-13-1494","article-title":"Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease","volume":"78","author":"Lee","year":"2014","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.hrtlng.2021.09.005_bib0013","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4070\/kcj.2016.0406","article-title":"Combining potent statin therapy with other drugs to optimize simultaneous cardiovascular and metabolic benefits while minimizing adverse events","volume":"47","author":"Koh","year":"2017","journal-title":"Korean Circ J"},{"issue":"40","key":"10.1016\/j.hrtlng.2021.09.005_bib0014","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.2174\/1381612820666140620115756","article-title":"Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease","volume":"20","author":"Athyros","year":"2014","journal-title":"Curr Pharm Des"},{"issue":"23","key":"10.1016\/j.hrtlng.2021.09.005_bib0015","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"Officers","year":"2002","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.hrtlng.2021.09.005_bib0016","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"issue":"9246","key":"10.1016\/j.hrtlng.2021.09.005_bib0017","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"issue":"9395","key":"10.1016\/j.hrtlng.2021.09.005_bib0018","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hrtlng.2021.09.005_bib0019","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/ajh\/hpt212","article-title":"Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study","volume":"27","author":"Chowdhury","year":"2014","journal-title":"Am J Hypertens"},{"issue":"9489","key":"10.1016\/j.hrtlng.2021.09.005_bib0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hrtlng.2021.09.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000125","article-title":"Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study","volume":"2","author":"Cooper-DeHoff","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.hrtlng.2021.09.005_bib0022","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hrtlng.2021.09.005_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000438","article-title":"Statin use and risk of developing diabetes: results from the diabetes prevention program","volume":"5","author":"Crandall","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.hrtlng.2021.09.005_bib0024","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S2213-8587(15)00391-5","article-title":"Preventing new-onset diabetes in thiazide-treated patients","volume":"4","author":"Mancia","year":"2016","journal-title":"Lancet Diabetes Endo"},{"issue":"6","key":"10.1016\/j.hrtlng.2021.09.005_bib0025","first-page":"1077","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"29","author":"Sattar","year":"2010","journal-title":"Rev Port Cardiol"},{"issue":"1","key":"10.1016\/j.hrtlng.2021.09.005_bib0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_37_17","article-title":"Diabetes as \"Coronary artery disease risk equivalent\": a historical perspective","volume":"18","author":"Hajar","year":"2017","journal-title":"Heart Views"},{"issue":"20","key":"10.1016\/j.hrtlng.2021.09.005_bib0027","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/eurheartj\/ehr333","article-title":"The anglo-scandinavian cardiac outcomes trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K","volume":"32","author":"Sever","year":"2011","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hrtlng.2021.09.005_bib0028","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacl.2018.08.014","article-title":"Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study","volume":"13","author":"Ho","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.hrtlng.2021.09.005_bib0029","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.110.160291","article-title":"Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications","volume":"56","author":"Kostis","year":"2010","journal-title":"Hypertension"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014795632100248X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014795632100248X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:12:07Z","timestamp":1777489927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014795632100248X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"alternative-id":["S014795632100248X"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2021.09.005","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antihypertensive drug class in combination with lipid lowering treatment for primary prevention of cardiovascular disease in the elderly","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2021.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}